Enzymatic creatinine assays allow estimation of glomerular filtration rate in stages 1 and 2 chronic kidney disease using CKD-EPI equation

Nils Kuster a, Jean-Paul Cristol a,⁎, Etienne Cavalière b,c, Anne-Sophie Bargnoux a, Jean-Michel Halimi d, Marc Froissart e, Laurence Piéroni f, Pierre Delanaye b, on behalf of the Société Française de Biologie Clinique (SFBC)

a Department of Biochemistry, CHU Lapeyronie, Montpellier, France
b Department of Nephrology–Dialysis–Transplantation, University of Liège, CHU Sart Tilman, Liège, Belgium
c Department of Clinical Chemistry, University of Liège, CHU Sart Tilman, Liège, Belgium
d Service de néphrologie, CHR Bretonneau, Tours, France
e Physiologie Rénale, Hôpital Européen Georges Pompidou, APHP, Paris, France
f Biochimie métabolique, Groupe hospitalier Pitié Salpêtrière, APHP, Paris, France

A R T I C L E   I N F O

Article history:
Received 11 September 2013
Received in revised form 1 November 2013
Accepted 1 November 2013
Available online 10 November 2013

Keywords:
CKD-EPI
MDRD
Creatinine
Estimated glomerular filtration rate
Enzymatic assays

A B S T R A C T

The National Kidney Disease Education Program group demonstrated that MDRD equation is sensitive to creatinine measurement error, particularly at higher glomerular filtration rates. Thus, MDRD-based eGFR above 60 mL/min/1.73 m² should not be reported numerically. However, little is known about the impact of analytical error on CKD-EPI-based estimates. This study aimed at assessing the impact of analytical characteristics (bias and imprecision) of 12 enzymatic and 4 compensated Jaffe previously characterized creatinine assays on MDRD and CKD-EPI eGFR.

In a simulation study, the impact of analytical error was assessed on a hospital population of 24 084 patients. Ability using each assay to correctly classify patients according to chronic kidney disease (CKD) stages was evaluated.

For eGFR between 60 and 90 mL/min/1.73 m², both equations were sensitive to analytical error. Compensated Jaffe assays displayed high bias in this range and led to poorer sensitivity/specificity for classification according to CKD stages than enzymatic assays. As compared to MDRD equation, CKD-EPI equation decreases impact of analytical error in creatinine measurement above 90 mL/min/1.73 m².

Compensated Jaffe creatinine assays lead to important errors in eGFR and should be avoided. Accurate enzymatic assays allow estimation of eGFR until 90 mL/min/1.73 m² with MDRD and 120 mL/min/1.73 m² with CKD-EPI equation.

© 2013 Elsevier B.V. All rights reserved.

1. Introduction

Chronic kidney disease (CKD) is associated with increased risk of cardiovascular events and overall mortality [1]. Since reliable methods to measure glomerular filtration rate (GFR) are expensive and difficult, it is assessed from serum creatinine (Scr) level in clinical practice [2]. However, Scr is also influenced by gender, age, muscle mass and ethnicity. To overcome these potential biases, equations have been developed to correct Scr for these factors and therefore provide Scr-based estimated GFR (eGFR).

Modification of Diet in Renal Disease (MDRD) [3] and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) [4] equations are automatically reported by laboratories in many countries. Scr is the most important variable in all these equations. Moreover, the relationship between Scr and GFR is exponential. Therefore, errors or imprecision in Scr measurements could strongly impact eGFR results, especially in the low Scr levels (high GFR values). As a result, the National Kidney Disease Education Program (NKDEP) working group recommended in 2006 not to report eGFR higher than 60 mL/min/1.73 m² numerically [5]. At this time, two types of analytical errors were recognized regarding the measurement of Scr: the analytical imprecision which is inherent to any biological measurement and the bias which is the systematic error due to difference in calibration. Regarding this last point, improvements have been realized in the last years with a standardization of the measurement with the so-called Isotope Dilution Mass Spectrometry (IDMS) traceability. Even if many manufacturers...
claim their Scr assays are well IDMS traceable, we have in fact relatively few external and independent proofs of it. Recently, the “Société Française de Biologie Clinique (SFBC)” working group reported evaluations of currently available IDMS-traceable Scr assays, especially focusing on enzymatic and compensated Jaffe methods [6,7]. If correct traceability has been found for most enzymatic methods, the results were less accurate for the compensated Jaffe methods. Also regarding imprecision, there are reasons to think that enzymatic methods better perform than Jaffe methods which are susceptible to pseudochromogen interferences [8,9]. Therefore, we think that it still makes sense to study the analytical error of Scr and the impact on the GFR estimating equations. In other words, we want to check if, from an analytical point of view, reporting eGFR results above 60 mL/min/1.73 m² is suitable in 2013 after improvements in standardization. Also, we analyzed potential differences between MDRD and CKD-EPI equations, the last one being now recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines [10]. The CKD-EPI equation was still not available when NKDEP recommended not to report eGFR ≥60 mL/min/1.73 m² numerically.

2. Material and methods

2.1. Creatinine measurements

The analytical performances of 16 IDMS-traceable analyzers/Scr assays couples (12 enzymatic: Abbott/Abbott, Beckman Coulter/Sentinel Diagnostics, FisherKonelab/Kone, Olympus AU 2700/Diasys, Olympus AU 2700/Olympus, Olympus AU 2700/Randox, OrthoClinical/OrthoClinical, Roche Cobas 6000/Roche, Roche Modular/Diasys, Roche Modular/Roche, Siemens Advia/Siemens; Siemens RXL/Siemens; 4 compensated Jaffe: Siemens Advia/Siemens, Roche Cobas 6000/Compensated Jaffe, Roche Cobas 6000/Compensated Jaffe, Roche Modular/Compensated Jaffe, Siemens Advia/Compensated Jaffe) have been reported by the SFBC working group and compared to performances’ characteristics proposed by NKDEP on the basis of biological variations of Scr [6,7]. Briefly, Scr level was assigned by gas chromatography IDMS (GC-IDMS) in the Laboratoire National de Métrologie et d’Essais in five plasma pools ranging from 35.9 to 174.5 μmol/L. The pools were then shipped to the laboratories involved in the study. For each assay, Scr level was determined for each pool in 3 laboratories, by 3 repeated measurements, 3 consecutive days. From these data, biasAssay (mean difference from IDMS assigned value) and sdAssay (standard deviation of the measurements) were computed.

2.2. Study population

Impact of analytical error on eGFR in was assessed using an unselected cohort of patients in whom Scr has been measured in the laboratory of biochemistry, Lapeyronie hospital, CHRU Montpellier, France. The measurements were performed between September, 1st and December, 31st, 2012 using an enzymatic Roche assay on a Cobas 8000 modular analyzer. From an initial database of 87842 measurements, only patients aged over 18 years old and measured Scr levels lower than 200 μmol/L were selected in order to match with the SFBC Scr pool levels. For each patient, only the first measurement was kept, leading to a final population of 24 084 patients.

2.3. Ethical statement

Patients Scr measurements were obtained from the routine laboratory database. No permission was required by our institution’s Ethics Committee as the database was fully anonymous and no personal information was collected for this study.

2.4. GFR estimation

eGFR was computed using MDRD and CKD-EPI equations. Re-expressed four-variable MDRD equation for use with IDMS-traceable assays [11] is expressed as:

\[
eGFR = 30849 \times \frac{Scr^{1.54}}{Age^{-0.203}} \times \frac{1}{1+65.17 \times \frac{Scr}{175.1}} \text{ if Female} \]

CKD-EPI equation [4] can be expressed in a single equation:

\[
eGFR = 141 \times \min \left( \frac{Scr}{K} \right)^{\alpha} \times \max \left( \frac{Scr}{K} \right)^{-1.209} \times 0.995^{4e}\left(1+\frac{Scr}{K}\right)^2 \text{ if Female} \left| 1.159 \text{ if Black} \right|
\]

With Scr in μmol/L, K is 62 for females and 80 for males, α is −0.329 for females and −0.411 for males, min indicates the minimum of Scr/K or 1 and max indicates the maximum.

2.5. Study design

For each assay, estimations of bias and imprecision for Scr levels between 20 and 200 μmol/L were extrapolated from the results of the SFBC study.

Table 1

Analytical performances of creatinine assays. Total error for each assay at each creatinine level was computed through Monte-Carlo simulations with respect to bias and imprecision. According to the National kidney Disease Education Program, optimum, desirable and minimum goals are 3.8%, 7.6% and 11.4%, respectively.

<table>
<thead>
<tr>
<th>Methode</th>
<th>Total error (%)</th>
<th>Pool 1 (35.9 μmol/L)</th>
<th>Pool 2 (74.4 μmol/L)</th>
<th>Pool 3 (97.9 μmol/L)</th>
<th>Pool 4 (149.7 μmol/L)</th>
<th>Pool 5 (174.5 μmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott/Abbott</td>
<td>3.6</td>
<td>6.5</td>
<td>5</td>
<td>3.8</td>
<td>6.7</td>
<td></td>
</tr>
<tr>
<td>Beckman Coulter/Sentinel Diagnostics</td>
<td>7</td>
<td>11.1</td>
<td>7.6</td>
<td>4.3</td>
<td>5.4</td>
<td></td>
</tr>
<tr>
<td>FisherKonelab/Kone</td>
<td>19.5</td>
<td>7.4</td>
<td>5.9</td>
<td>8.3</td>
<td>5.3</td>
<td></td>
</tr>
<tr>
<td>Olympus AU 2700/Olympus, Olympus AU 2700/Randox, OrthoClinical/OrthoClinical</td>
<td>19.5</td>
<td>11.6</td>
<td>9.5</td>
<td>3.6</td>
<td>4.2</td>
<td></td>
</tr>
<tr>
<td>Olympus AU 2700/Diasys</td>
<td>18.5</td>
<td>12.3</td>
<td>8.3</td>
<td>4.4</td>
<td>4.8</td>
<td></td>
</tr>
<tr>
<td>Olympus AU 2700/Olympus</td>
<td>8.9</td>
<td>4.1</td>
<td>5.4</td>
<td>3</td>
<td>2.7</td>
<td></td>
</tr>
<tr>
<td>Olympus AU 2700/Randox</td>
<td>12</td>
<td>8.8</td>
<td>8.9</td>
<td>6.7</td>
<td>8.4</td>
<td></td>
</tr>
<tr>
<td>OrthoClinical/OrthoClinical</td>
<td>25.4</td>
<td>7</td>
<td>4.8</td>
<td>9</td>
<td>9.1</td>
<td></td>
</tr>
<tr>
<td>Roche Cobas 6000/Compensated Jaffe</td>
<td>18.1</td>
<td>12.5</td>
<td>11.5</td>
<td>7.4</td>
<td>4.6</td>
<td></td>
</tr>
<tr>
<td>Roche Cobas 6000/Roche</td>
<td>6.5</td>
<td>4.7</td>
<td>4</td>
<td>4.8</td>
<td>2.9</td>
<td></td>
</tr>
<tr>
<td>Roche Modular/Compensated Jaffe</td>
<td>19.5</td>
<td>11.7</td>
<td>10.6</td>
<td>5.1</td>
<td>4.4</td>
<td></td>
</tr>
<tr>
<td>Roche Modular/Diasys</td>
<td>10.9</td>
<td>6.5</td>
<td>6.1</td>
<td>3.9</td>
<td>3.7</td>
<td></td>
</tr>
<tr>
<td>Roche Modular/Roche</td>
<td>8.3</td>
<td>3.2</td>
<td>3.9</td>
<td>2.7</td>
<td>2.7</td>
<td></td>
</tr>
<tr>
<td>Siemens Advia/Compensated Jaffe</td>
<td>15.3</td>
<td>10.9</td>
<td>11.8</td>
<td>3.7</td>
<td>3.6</td>
<td></td>
</tr>
<tr>
<td>Siemens Advia/Siemens</td>
<td>5.7</td>
<td>4.2</td>
<td>3.8</td>
<td>4.8</td>
<td>4.3</td>
<td></td>
</tr>
<tr>
<td>Siemens RXL/Siemens</td>
<td>10.2</td>
<td>8.7</td>
<td>6.9</td>
<td>7.2</td>
<td>5.9</td>
<td></td>
</tr>
</tbody>
</table>
In the study population, Scr measurement was carried out on a Cobas 6000 modular analyzer (c701 module) using the same reagent as the Roche enzymatic assay assessed by the SPBC study on a Cobas 6000 (c501 module). Although we cannot rule out a difference owing to platform and/or packaging, we assumed that the bias was similar in the two systems. Despite this limitation, subtracting the bias of Roche 6000 (c501 module) from the results measured in patients, Scr was computed through random generation of values following a normal distribution with mean equal to the bias and standard deviation equal to precision of each assay. Sensitivity against specificity for classification of patients according to CKD stages was evaluated.

Table 2

<table>
<thead>
<tr>
<th>Method</th>
<th>Assay type</th>
<th>MDRD</th>
<th>CKD-EPI</th>
<th>Assay type</th>
<th>MDRD</th>
<th>CKD-EPI</th>
<th>Assay type</th>
<th>MDRD</th>
<th>CKD-EPI</th>
<th>Assay type</th>
<th>MDRD</th>
<th>CKD-EPI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>60 mL/min/1.73 m² cutoff (%)&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td>90 mL/min/1.73 m² cutoff (%)&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td>% patients with error below 10% of eGFRRef&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sens</td>
<td>Spec</td>
<td>Sens</td>
<td>Spec</td>
<td>Sens</td>
<td>Spec</td>
<td>Sens</td>
<td>Spec</td>
<td>Sens</td>
<td>Spec</td>
<td>Sens</td>
</tr>
<tr>
<td>Abt/Abt</td>
<td></td>
<td>91.5</td>
<td>93.8</td>
<td>92.2</td>
<td>94.2</td>
<td>92.9</td>
<td>94.9</td>
<td>93.3</td>
<td>95.1</td>
<td>93.8</td>
<td>95.6</td>
<td>93.0</td>
</tr>
<tr>
<td>Beckman Coulter/Sentinel Diagnostics</td>
<td></td>
<td>97.3</td>
<td>99.6</td>
<td>98.1</td>
<td>99.6</td>
<td>97.7</td>
<td>99.6</td>
<td>97.2</td>
<td>99.2</td>
<td>97.7</td>
<td>99.7</td>
<td>97.4</td>
</tr>
<tr>
<td>FisherKonelab/Kone</td>
<td></td>
<td>97.5</td>
<td>99.6</td>
<td>98.2</td>
<td>99.6</td>
<td>97.2</td>
<td>99.6</td>
<td>96.7</td>
<td>99.4</td>
<td>97.2</td>
<td>99.4</td>
<td>96.7</td>
</tr>
<tr>
<td>Olympus AU 2700/Compensated Jaffe</td>
<td></td>
<td>88.9</td>
<td>93.9</td>
<td>90.1</td>
<td>94.9</td>
<td>92.2</td>
<td>94.9</td>
<td>90.7</td>
<td>94.0</td>
<td>92.6</td>
<td>94.0</td>
<td>90.7</td>
</tr>
<tr>
<td>Olympus AU 2700/Diasys</td>
<td></td>
<td>95.7</td>
<td>97.6</td>
<td>98.2</td>
<td>99.6</td>
<td>97.2</td>
<td>99.6</td>
<td>95.7</td>
<td>97.2</td>
<td>95.7</td>
<td>97.2</td>
<td>95.7</td>
</tr>
<tr>
<td>Olympus AU 2700/Orthoclinical/OrthoClinical</td>
<td></td>
<td>97.5</td>
<td>98.6</td>
<td>98.6</td>
<td>99.6</td>
<td>98.2</td>
<td>99.6</td>
<td>98.6</td>
<td>99.6</td>
<td>98.2</td>
<td>99.6</td>
<td>98.6</td>
</tr>
<tr>
<td>Roche Cobas 6000/Compensated Jaffe</td>
<td></td>
<td>99.5</td>
<td>93.8</td>
<td>99.2</td>
<td>95.5</td>
<td>99.5</td>
<td>93.8</td>
<td>99.2</td>
<td>95.5</td>
<td>99.5</td>
<td>93.8</td>
<td>99.2</td>
</tr>
<tr>
<td>Roche Cobas 6000/Roche</td>
<td></td>
<td>98.4</td>
<td>99.5</td>
<td>98.5</td>
<td>99.5</td>
<td>98.5</td>
<td>99.5</td>
<td>98.5</td>
<td>99.5</td>
<td>98.5</td>
<td>99.5</td>
<td>98.5</td>
</tr>
<tr>
<td>Roche Modular/Compensated Jaffe</td>
<td></td>
<td>99.5</td>
<td>93.8</td>
<td>99.5</td>
<td>95.5</td>
<td>99.5</td>
<td>93.8</td>
<td>99.5</td>
<td>95.5</td>
<td>99.5</td>
<td>93.8</td>
<td>99.5</td>
</tr>
<tr>
<td>Roche Modular/Diasys</td>
<td></td>
<td>97.6</td>
<td>98.6</td>
<td>97.6</td>
<td>99.6</td>
<td>97.6</td>
<td>98.6</td>
<td>97.6</td>
<td>99.6</td>
<td>97.6</td>
<td>98.6</td>
<td>97.6</td>
</tr>
<tr>
<td>Roche Modular/Roche</td>
<td></td>
<td>99.6</td>
<td>99.7</td>
<td>99.7</td>
<td>99.7</td>
<td>99.7</td>
<td>99.7</td>
<td>99.7</td>
<td>99.7</td>
<td>99.7</td>
<td>99.7</td>
<td>99.7</td>
</tr>
<tr>
<td>Siemens Advia/Compensated Jaffe</td>
<td></td>
<td>99.4</td>
<td>96.2</td>
<td>99.4</td>
<td>96.2</td>
<td>99.4</td>
<td>96.2</td>
<td>99.4</td>
<td>96.2</td>
<td>99.4</td>
<td>96.2</td>
<td>99.4</td>
</tr>
<tr>
<td>Siemens Advia/Siemens</td>
<td></td>
<td>97.7</td>
<td>99.1</td>
<td>97.7</td>
<td>99.1</td>
<td>97.7</td>
<td>99.1</td>
<td>97.7</td>
<td>99.1</td>
<td>97.7</td>
<td>99.1</td>
<td>97.7</td>
</tr>
<tr>
<td>Siemens RXL/Siemens</td>
<td></td>
<td>93.4</td>
<td>95.8</td>
<td>93.4</td>
<td>95.8</td>
<td>93.4</td>
<td>95.8</td>
<td>93.4</td>
<td>95.8</td>
<td>93.4</td>
<td>95.8</td>
<td>93.4</td>
</tr>
</tbody>
</table>

Fig. 1. Classification accuracy according to assay and equation. Sensitivity against specificity of each assay to detect estimated glomerular filtration rate lower than 90 mL/min/1.73 m² in the study population is shown for MDRD and CKD-EPI equations. Abbreviations: Abt/Abt, Abbott/Abbott; BC/Sent, Beckman Coulter/Sentinel Diagnostics; FK/K, FisherKonelab/Kone; Olympus/CJ, Olympus AU2700/Compensated Jaffe; Olmp/Dia, Olympus AU2700/Diasys; Olmp/Olmp, Olympus AU2700/Olympus; Olmp/Rdx, Olympus AU2700/Randox; Ort/Ort, Orthoclinical/OrthoClinical; CBS/CJ, Roche Cobas 6000/Compensated Jaffe; CBS/Rch, Roche Cobas 6000/Roche; Mdi/CJ, Roche Modular/Compensated Jaffe; Mdi/Dia, Roche Modular/Diasys; Mdi/Rch, Roche Modular/Roche; Adv/CJ, Siemens Advia/Compensated Jaffe; Adv/Smn, Siemens Advia/Siemens; RXL/Smn, Siemens RXL/Siemens.

2.6. Statistical analysis

Total error (TE) was computed for each assay and pool was defined as the 95th percentile of the absolute errors in a random sample of size 10 000 from a normal distribution with mean equal to the bias and standard deviation equal to imprecision of each assay.

Visual inspection of the data from previous SFBC studies[6,7] indicated that bias and imprecision were not linearly related to Scr levels. Bias and imprecision in the range of 20–200 μmol/L were extrapolated using locally-weighted polynomial regressions. ScrRef was computed by subtracting bias observed for the instrument used in our laboratory to the results measured in patients. ScrRef was computed through random generation of values following a normal distribution with mean equal to ScrRef + Bias and standard deviation equal to SdAssay pop.

Median, 2.5th and 97.5th percentiles of the difference between eGFRRef and eGFRRef were assessed using nonparametric quantile regression with B-splines (rqss, quantreg package). Ability to correctly
classify patients according to KDIGO CKD stages using each assay was assessed through computation of sensitivity and specificity to predict eGFR lower than 60 and 90 mL/min/1.73 m². Accuracy was assessed as the percentage of estimates that differed by less than 10% from eGFR_ref. All analysis was performed using R 2.15 (Vienna, Austria).

3. Results

Between September, 1st, 2012 and December, 31st, 2012, Scr was measured in 24084 patients aged over 18 years in the Department of Biochemistry, Lapeyronie University Hospital, Montpellier, France. Scr measurement was performed using a Roche enzymatic assay on a Cobas 8000 modular analyzer (Hoffman-La Roche, Basel, Switzerland). Mean age of patients was 55 years old (minimum – maximum, 18–105). Thirteen thousand height hundred six (57.3%) patients were aged 18 to 60 years, 5810 (24.1%), were aged 61 to 75 years and 4468 (18.6%) were aged 76 years or older. Gender was male in 12049 patients (50.0%). According to the routinely reported CKD-EPI based eGFR, 4000 (16.6%) patients had eGFR < 60 mL/min/1.73 m², 8171 (33.9%) had eGFR in the range of 60–89 mL/min/1.73 m² and 11913 (49.5%) had eGFR greater than 90 mL/min/1.73 m².

3.1. Performances of currently available creatinine assays

TE for each assay at each Scr pool level is shown in Table 1. Seven of the 16 assays respect the NKDEP minimum goal of 11.4% [5] at each Scr level, from which only 3 also respect the desirable threshold of 7.6%. No assay presented a TE lower than that of the optimal 3.8% goal at all Scr levels. Maximal error is frequently found at lowest Scr level (pool 1). At pool 2 level, 3 assays (Beckman Coulter/Sentinel Diagnostics, Roche

Fig. 2. Error in estimated glomerular filtration rate according to assay and equation in the study population. Difference between simulated estimated glomerular filtration rate with respect to analytical error of each assay (eGFRassay) and reference eGFR (eGFRref) in the population is represented against eGFRassay. Solid lines represent CKD-EPI equation and dashed lines represent MDRD equation. For each equation the 2.5th, 50th and 97.5th percentiles of the differences are shown. Letters in bottom left corner of each panel indicate the type of assay. E: enzymatic assay, J: Compensated Jaffe assay.

92 N. Kuster et al. / Clinica Chimica Acta 428 (2014) 89–95
Modular/Compensated Jaffe, Roche Cobas 6000/Compensated Jaffe presented TE greater than those of the minimum goal. Moreover, this minimum goal was not reached at pool 3 level with Siemens Advia/Compensated Jaffe assay.

3.2. Enzymatic creatinine assays improve GFR estimation above 60 mL/min/1.73 m²

As shown in Table 2, in the range of 60–90 mL/min/1.73 m², GFR was estimated with an error below 10% for the majority of patients with enzymatic assays using both equations (mean proportion, 97.5% and 96.6% with CKD-EPI and MDRD, respectively). Compensated Jaffe assays did not allow this level of accuracy (mean proportion, 82.5% and 78.9% with CKD-EPI and MDRD, respectively).

As shown in Fig. 1, compensated Jaffe assays were associated with the lowest ability to correctly classify patients as having eGFR below 90 mL/min/1.73 m², because of a lack of sensitivity (compensated Jaffe/Olympus AU2700) or specificity (Compensated Jaffe reagents on Siemens Advia, Roche Modular and Roche Cobas 6000 analyzers). By contrast, some enzymatic assays displayed both specificity and sensitivity above 95%, with MDRD and CKD-EPI equations (Siemens Advia/Siemens and Roche Cobas 6000/Roche assays). At 60 mL/min/1.73 m², a similar pattern was observed, although compensated Jaffe reagents on Siemens Advia, Roche Modular and Roche Cobas 6000 analyzers yield to a better specificity (Table 2).

3.3. CKD-EPI equation reduces impact of analytical error at higher glomerular filtration rate

Error in eGFR caused by Scr analytical error in the study population is shown in Fig. 2. For eGFR below 75 mL/min/1.73 m², error was nearly identical with MDRD or CKD-EPI equation. For eGFR equal to 60 mL/min/1.73 m², bias, as reflected by median difference between reference eGFR (eGFRRef) and eGFR simulated for each assay (eGFRAssay) was similar, ranging between −5.2 and 2.0 mL/min/1.73 m² with MDRD equation and between −5.3 and 2.1 mL/min/1.73 m² with CKD-EPI equation. At higher values, median difference increased with eGFR when MDRD equation was used but was reduced with CKD-EPI equation. Maximal bias with CKD-EPI equation is observed for eGFR close to 75 mL/min/1.73 m². At 90 mL/min/1.73 m², median differences across the assays ranged between −9.0 and 3.7 mL/min/1.73 m² with MDRD equation and between −5.9 and 2.1 mL/min/1.73 m² with CKD-EPI equation. Impact of imprecision is also reduced with CKD-EPI equation at higher eGFR, as represented by narrower ranges between 2.5th and 97.5th percentiles. In the range of 90–120 mL/min/1.73 m², CKD-EPI equation and enzymatic assays allowed estimation of GFR.

Fig. 3. Gender-dependant influence of creatinine error on estimated glomerular filtration rate. Error in estimated glomerular filtration rate is represented against creatinine level with Siemens Advia/Enzymatic assay and Siemens Advia/Compensated Jaffe assay, using MDRD and CKD-EPI equations. Using CKD-EPI equation, impact of analytical error is reduced for creatinine levels lower than the gender-dependant CKD-EPI threshold (62 μmol/L in females and 80 μmol/L in males, vertical dashed lines).
with an error below 10% in almost all patients (mean across enzymatic assays, 98.9%) whereas MDRD equation was more impacted by analytical error (mean across enzymatic assays, 93.8%, Table 2).

4. Discussion

Since it has been demonstrated that mild to moderate CKD is associated with adverse clinical outcomes [12], the KDIGO working group recently decided not to combine stage 1–2 CKD [1]. Furthermore, reliable estimates of high eGFR are important for drug dosing [13]. A precise eGFR above 60 mL/min/1.73 m² is thus valuable, which led to the development of the CKD-EPI equation. In this study, our goal was to determine if the errors due to the Scr measurement were low enough to allow the laboratories to report numerical eGFR above 60 mL/min/1.73 m². This study is thus an analytical study with important clinical implications.

The studies performed by the SFBC working group have highlighted the improvement of Scr measurement using enzymatic assays but also pointed out that compensated Jaffe assays do not reach the required performances [6,7]. Our results extend these observations by focusing on the consequences on eGFR. Among the 16 assays tested, compensated Jaffe assays are characterized by poorer performances than their enzymatic counterparts. The design of the SFBC study, which allowed different assays to be evaluated on the same analyzer, permits to draw conclusions about assays independently of the analytic platform. In this study, Siemens enzymatic reagent with the Siemens Advia analyzer provided reliable results whereas the compensated Jaffe assay with the same analyzer yielded deeply biased results. Furthermore, 3 of the 4 compensated Jaffe assays tested (compensated Jaffe on Siemens Advia, Roche Modular and Roche Cobas 6000 analyzers) displayed an important negative bias for eGFR in the range of 60–90 mL/min/1.73 m², as a result of an overestimation of Scr level. This pattern underscores the difficulty for the manufacturers in correctly realigning these assays against the IDMS reference method. The necessity of this realignment pertains to the well known interference of ketones, glucose and proteins with the Jaffe reaction [14]. Almost all the available assays are now supposed to be traceable to IDMS. Nevertheless, our results indicate that all assays are not equivalent. Surprisingly, little attention has been paid to this question in a recent KDIGO conference report [10,15]. Our results are in line with previous studies concluding that compensated Jaffe assays should be replaced by enzymatic ones [9,16]. Conversely, a large proportion of enzymatic assays allow error in eGFR determination lower than 10% up to 90 mL/min/1.73 m² using both MDRD and CKD-EPI equations (Table 2). Enzymatic method allows reporting MDRD results numerically until 90 mL/min/1.73 m² which is an improvement compared to prior recommendation of the NKDEP [5].

Our study also demonstrates that the impact of Scr analytical error depends on the equation used. CKD-EPI drastically decreases the impact of Scr measurement error at eGFR above 90 mL/min/1.73 m². Maximal susceptibility to analytical error is for Scr close to the threshold between the two slopes, 62 μmol/L in females and 80 μmol/L in males, which correspond to eGFR of 120 mL/min/1.73 m² at age 20 and 75 mL/min/1.73 m² at age 90 (Fig. 3). This observation comes from the mathematical model used to develop the equation. The lower exponent applied to Scr values makes the eGFR far less impacted by the Scr measurement error (Fig. 4, Panel A) and explains the lower

Fig. 4. Age-dependant effect of systematic creatinine error on estimated glomerular filtration rate Panel A shows the error in eGFR caused by a systematic 4 μmol/L error in creatinine determination with MDRD (dashed lines) and CKD-EPI (solid lines) equations for a male aged 30, 60 and 90 years. Panel B shows the mean error in eGFR observed with MDRD (dashed lines) and CKD-EPI (solid lines) equations in corresponding age groups in the study population using Siemens Advia/Compensated Jaffe assay, which presents a bias close to 4 μmol/L. Improvement of error caused by creatinine measurement is observed at lower eGFR when age increases. This is explained by the definition of the CKD-EPI threshold on the creatinine scale, corresponding to age-dependant eGFR.
error at higher eGFR levels observed in our study (Fig. 4, Panel B). Noteworthy, because the eGFR corresponding to the CKD-EPI threshold depends on age, improved robustness is mainly significant in patients aged 60 or older. The use of CKD-EPI equation in our population leads to a reduction of both bias and imprecision for eGFR higher than 90 mL/min/1.73 m², therefore allowing estimation of eGFR up to 120 mL/min/1.73 m².

NKDEP recommendations suggest laboratory to provide GFR estimation along with Scr results [5,17]. Little is known about the impact of analytical Scr determination on CKD-EPI equation, particularly at higher GFR. This study allows an estimation of variations of eGFR caused by analytical errors with a wide panel of assays in a large hospital-based population. Some limitations must nevertheless be acknowledged. Mainly, no GFR measured by reference methods was used and therefore impact of analytical variations could only be assessed beside eGFR calculated from IDMS Scr level. Our study showed potential superiority for the CKD-EPI equation in terms of precision compared to the MDRD one. However, this superiority is both analytical and theoretical.

In other words, we showed that enzymatic methods allow giving numerical results with the MDRD equation until 90 mL/min/1.73 m². This does not mean that this result is clinically accurate, for example in comparison with measured GFR and in fact this equation has been shown to underestimate “true” GFR in high GFR values. In the same vein, the superiority of the CKD-EPI equation over MDRD is purely analytical and has not been confirmed by all authors [18]. Moreover, the added analytical value of the CKD-EPI equation over the MDRD one would be relevant only in the higher CKD stage (above 90 mL/min/1.73 m²). We should also keep in mind that CKD-EPI equation, as well as MDRD, has been derived mainly from Scr measurement performed with Jaffe assays, secondarily realign against enzymatic assays [4,11]. Further studies in clinical settings may be useful in order to generalize our findings by considering together the analytical errors and the errors inherent to each equation and the errors inherent to the study of various populations.

5. Conclusions

Our results highlight that, despite an important effort of standardization, choice of Scr assay still greatly impacts accuracy of Scr-based eGFR. This study also confirms limitations of compensated Jaffe Scr assays.

Results of this study support the use of CKD-EPI equation rather than MDRD, allowing accurate results at eGFR above 90 mL/min/1.73 m². Once again, the better accuracy of the CKD-EPI equation is purely analytical. One of the most recent recommendations published comes from the Australasian Creatinine Consensus Working Group which recommended the use of CKD-EPI equation and a numerical expression at least up to 90 mL/min/1.73 m² [19]. Our study provides a basis for such recommendations and even extends it to eGFR as high as 120 mL/min/1.73 m², as long as an accurate enzymatic assay is used.

References